Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

NCT06737042 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

285

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity and Overweight

Interventions

DRUG: GZR18
DRUG: Tirzepatide

Sponsor

Gan and Lee Pharmaceuticals, USA